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Abstract
The aim of this study was to define the concordance between tissue microarrays (TMAs) of different sizes and whole slide for 15
different antibodies in endometrial cancer and study the use of TMAs in preoperative endometrial samples. Cores of preoperative
and hysterectomy specimens of 14 endometrial cancer and three atypical hyperplasia cases were collected in TMA blocks. Two
0.6-mm and two 2.0-mm cores were used from each sample. Different antibodies were tested in TMAs and compared with results
of whole slides of hysterectomy. Tested antibodies were as follows: ER, PR, p53, Ki-67, MLH1, PMS2, MSH2, MSH6,
ARID1A, stathmin, IMP3, L1CAM, PTEN, β-catenin, and p16. Seventeen cases with four cores per paraffin block (both 0.6
and 2.0 mm in duplicate) and 15 different antibodies resulted in a total of 1020 cores for both preoperative and hysterectomy
specimen. Overall, 2.0-mm cores were more assessable for evaluation than 0.6-mm cores (96.0 versus 79.5%, p < 0.01). For most
antibodies, a substantial to good agreement between hysterectomy TMA and whole slide was present, with lowest agreement for
p16 and stathmin and perfect agreement for mismatch repair proteins. Preoperative TMAs showed for most antibodies moderate
to perfect agreement with hysterectomy TMAs. In conclusion, 2.0-mm cores are the preferred size for immunohistochemical
studies in endometrial cancer. For all tested antibodies, TMAs are a good alternative for whole slide analysis in scientific studies
with large patient cohorts, even in preoperative endometrial samples. However, caution is required for interpretation of TMA
results of p16 and stathmin.
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Introduction
In endometrial cancer, biomarkers may add information for
risk stratification for tailored treatment strategies [1]. Many
biomarkers for individualized treatment in endometrial cancer
were discovered recently [1]. To validate these biomarkers, we
need large-scale studies with examination of many samples
which requires a large amount of tissue and laboratory
consumables that induces high research costs. Tissue micro-
arrays (TMAs) are an efficient way to examine a large number
of cases on a single slide. In 1998Kononen et al. described the
use of TMAs for high-throughput, molecular characterization
of a large panel of tumor specimens [2].
Many studies have compared TMAs to whole sections
[3–6]. However, different core sizes for TMAs can be used
and limited information is available about comparison of dif-
ferent core sizes [7, 8]. Furthermore, primary treatment is
based on preoperative diagnosis, with a discordance between
preoperative and postoperative diagnosis in 15–40% of the
cases [9–12]. This can result in both over- and undertreatment.
Biomarkers might minimize this discordance. However, most
studies have studied new biomarkers in hysterectomy speci-
mens [3]. Yet, frequently, endometrial sampling reveals only
scant material [13, 14]. This makes the use of TMAs in pre-
operative endometrial samples a challenge.
The aim of the present study is to define the concordance
between TMAs of different sizes and whole slide for 15
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different antibodies and study the use of TMAs in preopera-
tive endometrial samples.
Material and methods
Tissue samples
Cases were retrieved from the pathology archive of the
Radboud university medical center, Nijmegen, the
Netherlands. Seventeen cases, 14 with primary endometrial
cancer and 3 with atypical hyperplasia of the endometrium
who have had preoperative endometrial sampling and hyster-
ectomy, were included in this study. We selected representa-
tive cases (n = 14) of different types of endometrial cancer,
including four endometrioid endometrial cancer (EEC) grade
1, four EEC grade 2, two EEC grade 3, two serous carcinoma
(USC), and two clear-cell carcinoma (CCC). From each case,
a representative block with tumor of both the preoperative and
the hysterectomy specimen was collected. We selected only
cases with sufficient tumor tissue in the paraffin block. The
cases were reviewed by a specialized gynecopathologist (JB).
Tissue microarray construction
From each case, four representative areas with tumor or hy-
perplasia were encircled on the hematoxylin and eosin (H&E)
slide of both the preoperative and hysterectomy specimen.
TMAs were constructed using the TMA grand master
(3DHISTECH, Budapest, Hungary). From each correspond-
ing paraffin block, two 0.6-mm and two 2.0-mm cores were
made. This resulted in four TMA blocks: one TMA block
containing 17 duplicate 0.6-mm cores of the preoperative
specimen, one TMA block containing 17 duplicate 2.0-mm
cores of the preoperative specimen, one TMA block contain-
ing 17 duplicate 0.6-mm cores of the hysterectomy specimen,
and one TMA block containing 17 duplicate 2.0-mm cores of
the hysterectomy specimen. Seventeen cases with four cores
per paraffin block (both 0.6 and 2.0 mm in duplicate) and 15
different antibodies result in a total of 1020 stained cores for
both preoperative and hysterectomy specimen.
Immunohistochemistry and scoring
Immunohistochemistry was performed on 4-μm sections of
the four TMA blocks and the corresponding whole slides of
the hysterectomy, using 15 different antibodies (Table 1). In
short, antigen retrieval was performed and endogenous perox-
idase blocked with hydrogen peroxide. Slides were incubated
with the primary antibody for 1 h at room temperature.
Subsequently, they were incubated with PowerVision+ Poly-
HRP and visualized with PowerVision DAB substrate solu-
tion (Leica Biosystems, Buffalo Grove, IL, USA). Finally, the
slides were counterstained with hematoxylin, dehydrated, and
mounted.
All TMA cores and whole slides were scored twice, by two
independent investigators (NCMV in combination with JB,
IDN, or AAMW). In case of discrepancies, the slides were
discussed together and a consensus score was made. We have
used a semiquantitative scoring index to evaluate the immu-
nohistochemical staining, with exception of the mismatch re-
pair (MMR) proteins, ARID1A, and Ki-67. The scoring index
(0–9) was obtained by the product of intensity, graded from 0
(no staining), 1 (weak staining), 2 (moderate staining), to 3
(strong staining), and area of tumor with this staining intensity,
graded from 0 (no positive tumor cells), 1 (1–10% positive
tumor cells), 2 (11–50% positive tumor cells), to 3 (> 50%
positive tumor cells). We designated cutoff values of the scor-
ings index (0–9) for positivity/high expression as follows: ER,
PR, IMP3, L1CAM, and p16 scoring index ≥ 4, PTEN ≥ 2, β-
catenin ≥ 6, and stathmin ≥ 7. For p53, aberrant staining was
defined as a scorings index ≥ 5 or complete negative staining.
For ARID1A and MMR (MLH1, PMS2, MSH2 and MSH6)
tumors were considered aberrant if tumor cells showed com-
plete absence of nuclear staining, with positive internal control
(stromal cells). Tumors were considered positive for ARID1A
and MMR if there was any positive tumor cell with nuclear
staining, regardless of intensity. Cases with negative tumor
cells and no internal control were scored as indeterminate.
For Ki-67, the percentage of positive tumor cells was deter-
mined. Results of duplicate cores of each tumor were com-
bined to give a tumor score. In case the two scores differed, the
mean of the two scores was used as the overall tumor score. If
one core was not assessable, the overall tumor score was that
of the remaining assessable core. Cores were considered as-
sessable if there was enough tumor tissue for evaluation of the
immunohistochemical staining. Cores were considered not as-
sessable in case of < 10% tumor cells in the core (“sampling
error,” e.g., only stroma) or when < 10% of the tissue was
present in the core (“absent core”).
Statistical analysis
Difference in assessability between 0.6- and 2.0-mm cores
was calculated with chi-squared test. The agreement between
the immunohistochemical score on TMA and whole slide, and
between preoperative and hysterectomy TMA, was deter-
mined by calculating Cohen’s kappa. Agreement was consid-
ered poor if κ < 0.2, fair if 0.21 < κ < 0.4, moderate if 0.41 < κ
< 0.6, substantial if 0.61 < κ < 0.8 and almost perfect if 0.81
< κ < 1.00. Since Ki-67 score was not dichotomized, the dif-
ference in Ki-67 score between whole slide and TMA was
calculated with the related-samplesWilcoxon signed rank test.
The difference in ratio between false positive and false nega-
tive cases was also calculated with the related-samples
Wilcoxon signed rank test. A p value of < 0.05 was considered
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to indicate statistical significance. Statistical analysis was
performed with SPSS version 22 (SPSS IBM, New York,
NY, USA).
Results
Assessability
Of the 1020 tumor cores with core size 0.6 mm, 811 were
assessable (79.5%), whereas 979 of the tumor cores with core
size 2.0 mm were assessable (96.0%) (p < 0.01). The differ-
ence in assessability was more prominent in the hysterectomy
TMAs than the preoperative TMAs; however, both show a
significant difference (p < 0.01). Of the hysterectomy TMAs
71.2% of the 0.6-mm cores and 98.6% of the 2.0-mm cores
was assessable, compared to respectively 87.8 and 93.3% of
the preoperative TMAs. The most common cause for a not
assessable core was tumor loss during process (10%). In only
1% of the cases, there was sampling error with less than 10%
tumor cells.
Interobserver variability
There was a substantial to almost perfect agreement between
the TMA score of the different investigators. Kappa values
varied between 0.72 for PTEN to 0.998 for Ki-67 (Table 1).
Heterogeneity
Overall, there was a good agreement between scores of cores
of the same size. The agreement varied per antibody, between
moderate for p16 to almost perfect for MLH1, PMS2, MSH2,
MSH6, β-catenin, IMP3, and ARID1A (Fig. 1). For some
antibodies, the agreement was better with larger cores com-
pared to 0.6-mm cores (PTEN, ARID1A, Stathmin, p53),
whereas others show better agreement with smaller cores
(ER, PR, MSH6).
Preoperative versus hysterectomy TMAs
The correlation between preoperative TMAs and hysterec-
tomy TMAs differs per antibody and varied from almost
perfect agreement for MLH1, PMS2, MSH2, β-catenin,
and ER to poor agreement for ARID1A, p53, and stathmin
(Fig. 2a, b). There were more false positive than false
negative cases on preoperative TMAs (p = 0.04). Overall,
9% of the cases were false positive and 5% were false
negative on preoperative TMA. False positive rates per
antibody varied from 0 to 36% and false negative rates
from 0 to 21%. ARID1A and P53 staining showed the
highest false positive rate (respectively 33 and 36%). For
Ki-67, the score was significantly higher on preoperative
TMA compared to hysterectomy TMA, both for 2.0- and
0.6-mm cores (p = 0.001). The median difference between
the Ki-67 score on preoperative TMA and hysterectomy
TMA was larger in 2.0-mm compared to 0.6-mm cores
(respectively 36 and 11, p < 0.05) (not shown in figure).
TMA versus whole slide of hysterectomy
For most antibodies, there was a substantial to good agree-
ment between hysterectomy TMA and whole slide, with
exception of stathmin, p16, and p53 (Figs. 2c, d and 3a).
Table 1 Antibodies used in this study
Antibody Staining pattern Clone Antigen retrieval Dilution Source Interobserver
variability (kappa)
ER Nuclear SP1 EDTA pH 9 1:80 Immunologic 0.959
PR Nuclear PgR636 EDTA pH 9 1:500 Dako 0.961
MLH1 Nuclear G168-15 EDTA pH 9 1:40 BD 0.894
PMS2 Nuclear A16-4 EDTA pH 9 1:100 BD 0.800
MSH2 Nuclear GB12 EDTA pH 9 1:20 Calbiochem 0.848
MSH6 Nuclear EPR3945 EDTA pH 9 1:1000 Abcam 0.763
PTEN Nuclear and cytoplasmic 6H2.1 EDTA pH 9 1:100 Dako 0.724
IMP3 Cytoplasmic 69.1 EDTA pH 9 1:50 Dako 0.912
β-Catenin Membranous and cytoplasmic 14/β-catenin EDTA pH 9 1:200 BD 0.911
L1CAM Membranous 14.10 EDTA pH 9 1:100 BioLegend 0.921
Ki-67 Nuclear MIB-1 Citrate pH 6.0 1:40 Dako 0.998
ARID1A Nuclear HPA005456 Citrate pH 6.0 1:100 Sigma 0.796
Stathmin Cytoplasmic 3351 Citrate pH 6.0 1:50 Cell Signaling 0.824
P53 Nuclear DO-7 Citrate pH 6.7 1:200 Immunologic 0.901
P16 Nuclear and cytoplasmic MX007 HIER pH 8.0 1:60 Immunologic 0.779
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Stathmin and p16 staining show a moderate to poor agree-
ment between TMA and whole slide of hysterectomy, de-
pending on the core size. For p16, all but one were scored
positive on whole slide. Four of the 14 assessable cases
were scored negative for p16 on 0.6-mm TMA cores
(Fig. 3b). For stathmin, all cases were scored negative on
2.0-mm TMA cores. Three of these 17 cases were scored
positive on whole slide. Most discrepancies for p53 were
seen for cases with complete negative, aberrant staining on
TMA and positive staining on whole slide (n = 4).
For Ki-67, the score was significantly lower on TMA
than on whole slide, for both 2.0- and 0.6-mm cores
(respectively p < 0.01) (Fig. 4). The median difference be-
tween the Ki-67 score on TMA and whole slide was 29
and 22 for 2.0- and 0.6-mm cores, respectively, which is
not significantly different.
Discussion
Overall, 2.0-mm cores were more assessable for evaluation
than 0.6 mm cores (96.0 versus 79.5%, p < 0.01). For
most antibodies, a substantial to good agreement between
hysterectomy TMA and whole slide was present. Preoperative
Fig. 1 Strength of agreement
between two cores of the same
size (kappa statistics). Green
indicates almost perfect
agreement, red indicates poor
agreement
Fig. 2 Preoperative versus hysterectomy TMA for 0.6 mm (a) and
2.0 mm (b) and TMA versus whole slide of hysterectomy for 0.6-mm
(c) and 2.0-mm cores (d). Green indicates no difference, red indicates
difference, and blue indicates not assessable cores. Percentages
represent the percentage of cores with a difference between
respespectively preoperative and hysterectomy TMA score and between
TMA and whole slide of hysterectomy
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TMAs showed for most antibodies moderate to perfect
agreement with hysterectomy TMAs.
TMAs are an efficient method to test new biomarkers in a
research setting, since it saves time, costs, and tissue [15]. This
last issue is also one of the concerns. Tumors can be heteroge-
neous and low density or diffuse tumors might be difficult to
sample. In endometrial cancer, many promising biomarkers
have been reported the last years [16–20]. Most of these bio-
markers have been studied in hysterectomy specimens, whereas
especially preoperative biomarkers might be clinically useful to
choose the best surgical treatment. Previous studies have report-
ed a significant correlation for stathmin, L1CAM, ER, and PR
expression between curettage and hysterectomy specimen [18,
21, 22]. However, although there is a correlation, expression
pattern is not completely overlapping, with a discordance rate
of 10% for L1CAM to 33% for stathmin. These percentages are
in line with the results of the present study. In general, we
reported more false positive than false negative cases on preop-
erative TMAs (respectively 9 and 5%). Although based on
small numbers, this difference was most pronounced for p53
and ARID1A. Studies that describe discrepancies between pre-
operative and hysterectomy specimen show different results
about the false positive and false negative rates [18, 21–23].
Differences in staining between preoperative and hysterectomy
specimen could be explained by differences in fixation or the
representativeness of the tissue. With endometrial sampling,
only the superficial part of the tumor is examined, whereas in
a hysterectomy specimen also the invasive front is examined.
Moreover, tumor heterogeneity can be a challenge when using
TMAs for biomarker studies. Distinction between true
intratumor heterogeneity and irregular staining can be challeng-
ing. In case of alternate groups of tumor cells with complete
Fig. 3 TMAversus whole slide of
hysterectomy. a Strength of
agreement between TMA and
whole slide of hysterectomy
(kappa statistics). b Case with
discrepancy between whole slide
and 0.6 mm TMA for p16 (two
0.6-mm core holes marked with
an asterisk). Whole slide showing
positive staining (scorings index
6), concordant positive 2.0-mm
cores (combined scorings index
6) and discrepant negative 0.6-
mm cores (combined scorings
index 3)
Fig. 4 Absolute difference in Ki-
67 score between TMA and
whole slide (ref.) per case. Each
bar represents a case, with in
black the 0.6-mm cores and in
gray 2.0-mm cores. In the most
right column, the median
difference in Ki-67 for all cases,
separated by core diameter
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negative and positive staining on the whole slide, we consid-
ered intratumor heterogeneity as the cause of discrepancy. In
case of a gradual decrease in staining intensity on whole slide,
we considered irregular staining the most likely cause of the
discrepancy. In our study, discrepancies between TMA and
hysterectomy could be attributed to both causes.
Although p16 is a heterogeneous staining, it still showed a
moderate agreement between the two cores. To decrease the
effect of heterogeneity on TMA score, investigators have the
dilemma to use more or larger cores or perform the staining on
whole slides. Especially for antibodies such as p16 and
stathmin, additional cores or staining on whole slide should
be considered to lower the chance of false negative cases.
There is no consensus on the optimal number of cores.
Kyndi et al. reported that a single core seems to be sufficient,
whereas Neves-Silva et al. reported that two cores per case is
the optimal number with regard to tissue loss and agreement
with whole slide [24, 25]. The same goes for core size. Most
studies report that smaller cores, in case assessable, are as
representative as larger cores. However, the relation between
core loss after immunohistochemical staining and core size is
less clear. Neves-Silva et al. shows more loss in 1.0-mm cores
than 2.0-mm cores, whereas Fonseca et al. reported that core
loss increases with increasing core size from 3 to 7% with
cores of respectively 1.0 and 3.0 mm [8, 24]. In the present
study, we reported more core loss when using 0.6-mm cores
compared to 2.0-mm cores. An explanation might be that
larger cores have better adhesion to the surrounding paraffin
of the donor block because of the larger diameter. Moreover,
core loss might also be dependent on the type of specimen
used. For example, TMAs of large solid tumors might show
more assessable cores than a TMA from a small biopsy.
Although the amount of preoperative tissue is often scant,
cores were lost in only 7 to 12% of the cases. This is in line
with literature that report 2–25% core loss [3, 5, 15, 26].
One of the limitations of this study is the small number of
cases. However, for most antibodies, there were positive and
negative cases. Only for β-catenin, all cases were positive,
which was expected, since Shaco-Levy reported beta-catenin
positivity in all endometrioid carcinomas and all proliferative
endometrium cases [27]. Due to the strong cytoplasmatic
staining for β-catenin, evaluation of nuclear staining was not
reliable. Therefore, only cytoplasmatic and membranous
staining was scored for β-catenin.
Per case, we have created duplicate cores of both 0.6 and
2.0 mm to gain information about the optimal number and size
of the TMA cores. We have not stained the whole slide of the
preoperative specimen because after punching out the cores
for the TMAs in most cases, only a limited amount of tumor
was left in the paraffin block. Therefore, we could only com-
pare the hysterectomy TMA to whole slide staining.
The strength of this study is the large number of cores
(1020) and antibodies that were studied. To our knowledge,
this is the first study that systematically studies the use of
TMAs for biomarkers studies in endometrial cancer, with spe-
cial attention to the use on preoperative tissue. Because of the
high discrepancy between preoperative and final diagnosis in
endometrial cancer, preoperative risk classification should be
improved to prevent over- and undertreatment. New bio-
markers might help to improve this risk classification [28].
TMAs might help in discovering and validating new bio-
markers, since most of the time, large patient cohorts are re-
quired for validation studies.
In conclusion, based on the more frequent loss of cores with
smaller core size, 2.0-mm cores are the preferred size for immu-
nohistochemical studies in endometrial cancer. Agreement be-
tween TMA and whole slide, and preoperative and hysterecto-
my TMAs varied per antibody, with lowest agreement for p16
and stathmin and perfect agreement for mismatch repair pro-
teins. For all tested antibodies TMAs are a good alternative for
whole slide analysis in scientific studies with large patient co-
horts, even in preoperative endometrial samples with clearly less
tissue than in a hysterectomy specimen. However, caution is
required for interpretation of TMA results of p16 and stathmin.
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